Radnostix acquires Lucerno Dynamics assets

Radnostix, a leader in radioisotope production and nuclear medicine solutions, announced the successful closing of its acquisition of key assets from Lucerno Dynamics. The acquired assets include the LARA System technology platform, ELLEXA Explorer software, and associated intellectual property. This strategic move aims to expand Radnostix's medical device portfolio, particularly in radiopharmaceutical and nuclear medicine applications, by developing practical delivery and monitoring solutions. The LARA System and ELLEXA software, clinically proven in nearly 50,000 administrations across various countries including Australia, Singapore, Japan, Europe, and the United States, are designed to improve patient safety by identifying and reducing extravasations of IV-administered radiopharmaceuticals. Shahe Bagerdjian, CEO of Radnostix, emphasized that this acquisition is a significant milestone in the company's strategy to become a comprehensive solutions provider in the rapidly growing theranostics delivery and administration market. Ron Lattanze, CEO of Lucerno Dynamics, expressed confidence in Radnostix's ability to ensure the long-term viability of their intellectual property.